Highlights Newsletter 2
This newsletter presents you the following key sessions:
-
Watch the video interview with prof. Bernard Escudier about an update of Checkmate 214:
efficacy and safety of nivolumab + ipilimumab versus sunitinib in treatment-naïve patients
with advanced or metastatic renal cell carcinoma -
Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma